TRENTON, N.J. - Johnson & Johnson said Tuesday it would reduce its global work force by up to 4 percent, or up to 4,820 jobs, to cut costs due to a slump in sales of its heart stents and its No. 2 drug, plus looming expirations for key drug patents.
The health care company, which employs about 120,500 people in 57 countries worldwide, predicted the restructuring would entail pretax charges totaling $550 million to $750 million in the second half of 2007 and would include additional, unspecified steps besides job cuts.
Excluding the charges, the New Brunswick, N.J.-based maker of contraceptives, contact lenses, prescription drugs and baby products still expects to meet …
Inga kommentarer:
Skicka en kommentar